Log in

PlusTherapeuticsInc . Stock Price, News & Analysis (NASDAQ:PSTV)

+0.09 (+3.50 %)
(As of 10/20/2019 02:42 PM ET)
Today's Range
Now: $2.66
50-Day Range
MA: $6.92
52-Week Range
Now: $2.66
Volume371,002 shs
Average Volume1.06 million shs
Market Capitalization$1.20 million
P/E RatioN/A
Dividend YieldN/A
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company's lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. It also engages in developing DoxoPLUS, an injectable generic PEGylated liposomal formulation of doxorubicin for the treatment of breast, ovarian, multiple myeloma, and Kaposi's sarcoma cancer. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:PSTV



Sales & Book Value

Annual Sales$3.67 million
Book Value$17.62 per share


Net Income$-12,630,000.00
Net Margins-492.45%


Market Cap$1.20 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive PSTV News and Ratings via Email

Sign-up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter.

PlusTherapeuticsInc . (NASDAQ:PSTV) Frequently Asked Questions

What is PlusTherapeuticsInc .'s stock symbol?

PlusTherapeuticsInc . trades on the NASDAQ under the ticker symbol "PSTV."

How were PlusTherapeuticsInc .'s earnings last quarter?

PlusTherapeuticsInc . (NASDAQ:PSTV) posted its quarterly earnings results on Thursday, August, 15th. The company reported ($5.12) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($9.75) by $4.63. The business earned $0.30 million during the quarter. PlusTherapeuticsInc . had a negative net margin of 492.45% and a negative return on equity of 546.87%. View PlusTherapeuticsInc .'s Earnings History.

When is PlusTherapeuticsInc .'s next earnings date?

PlusTherapeuticsInc . is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for PlusTherapeuticsInc ..

Has PlusTherapeuticsInc . been receiving favorable news coverage?

News coverage about PSTV stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. PlusTherapeuticsInc . earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for PlusTherapeuticsInc ..

Are investors shorting PlusTherapeuticsInc .?

PlusTherapeuticsInc . saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 43,400 shares, an increase of 84.7% from the August 30th total of 23,500 shares. Based on an average daily trading volume, of 589,100 shares, the short-interest ratio is presently 0.1 days. Currently, 5.6% of the shares of the stock are sold short. View PlusTherapeuticsInc .'s Current Options Chain.

Who are some of PlusTherapeuticsInc .'s key competitors?

What other stocks do shareholders of PlusTherapeuticsInc . own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PlusTherapeuticsInc . investors own include Bio-Path (BPTH), Aerie Pharmaceuticals (AERI), Moleculin Biotech (MBRX), Ocular Therapeutix (OCUL), U.S. Auto Parts Network (PRTS), VBI Vaccines (VBIV), Atossa Genetics (ATOS), Amarin (AMRN), Advanced Micro Devices (AMD) and Align Technology (ALGN).

Who are PlusTherapeuticsInc .'s key executives?

PlusTherapeuticsInc .'s management team includes the folowing people:
  • Dr. Marc H. Hedrick, CEO, Pres & Director (Age 56)
  • Mr. Alan Lins, Principal Financial & Accounting Officer, VP of Fin. and Controller
  • Dr. John K. Fraser Ph.D., Chief Scientist (Age 58)
  • Mr. Russ Havranek, VP of Global Marketing
  • Mr. Gary S. Titus, Advisor (Age 59)

How do I buy shares of PlusTherapeuticsInc .?

Shares of PSTV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PlusTherapeuticsInc .'s stock price today?

One share of PSTV stock can currently be purchased for approximately $2.66.

How big of a company is PlusTherapeuticsInc .?

PlusTherapeuticsInc . has a market capitalization of $1.20 million and generates $3.67 million in revenue each year. PlusTherapeuticsInc . employs 37 workers across the globe.View Additional Information About PlusTherapeuticsInc ..

What is PlusTherapeuticsInc .'s official website?

The official website for PlusTherapeuticsInc . is http://www.plustherapeutics.com/.

How can I contact PlusTherapeuticsInc .?

PlusTherapeuticsInc .'s mailing address is 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756. The company can be reached via phone at 737-255-7194 or via email at [email protected]

MarketBeat Community Rating for PlusTherapeuticsInc . (NASDAQ PSTV)

Community Ranking:  1.9 out of 5 (star star)
Outperform Votes:  15 (Thanks for Voting!)
Underperform Votes:  24 (Thanks for Voting!)
Total Votes:  39
MarketBeat's community ratings are surveys of what our community members think about PlusTherapeuticsInc . and other stocks. Vote "Outperform" if you believe PSTV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSTV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Featured Article: Operating Income

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel